Beyond BRCA: Gene Mutations in Breast Cancer

JULIA NANGIA, MD
Wednesday, February 07, 2018


The differences seen in just over 5 years in regards to the existing knowledge of non-BRCA genes are astronomical. Since then, there has been an explosion of knowledge about other genes, the 3 most common of which are PALB2, CHEK2, and ATM. In addition, Lynch Syndrome, which was thought to only be related to colon cancer shares genes that have been linked to breast cancer.

“The genetic hereditary cancer syndromes are much more complicated than we thought, and there are many, many more genes that would have an impact on how we follow women and potentially can prevent breast cancer in these women,” said Julie Nangia, MD, Assistant Professor of Medicine, Baylor College of Medicine.

Additionally, she says, FDA approval of PARP inhibitors - drugs made for BRCA mutation carriers - have caused a proliferation of research in all tumor types associated with BRCA and other mutations that are in those same pathways. These trials are pursuing treatments that could be less toxic, prevent the need for chemotherapy, and prevent recurrences.
 

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Blogs
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.